Baricitinib + Placebo

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Areata Alopecia

Conditions

Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical

Trial Timeline

Feb 27, 2023 → Aug 1, 2029

NCT ID

NCT05723198

About Baricitinib + Placebo

Baricitinib + Placebo is a phase 3 stage product being developed by Eli Lilly for Areata Alopecia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05723198. Target conditions include Areata Alopecia, Alopecia, Hypotrichosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07222332	Phase 3	Recruiting	Feb 5, 2026	Jul 1, 2028	Diabetes Mellitus, Type 1
NCT07222137	Phase 3	Recruiting	Jan 12, 2026	Jul 1, 2031	Diabetes Mellitus, Type 1
NCT05237388	Phase 2	Recruiting	Apr 20, 2023	Mar 31, 2026	Chronic Kidney Diseases
NCT05723198	Phase 3	Recruiting	Feb 27, 2023	Aug 1, 2029	Areata Alopecia
NCT04421027	Phase 3	Completed	Jun 12, 2020	Jun 10, 2021	COVID-19
NCT03843125	Phase 3	Terminated	Sep 9, 2019	Apr 1, 2022	Systemic Lupus Erythematosus
NCT03899259	Phase 3	Completed	Jul 8, 2019	Nov 19, 2024	Alopecia Areata
NCT03742973	Phase 2	Terminated	Mar 28, 2019	Sep 26, 2019	Primary Biliary Cholangitis
NCT03773978	Phase 3	Completed	Dec 17, 2018	Jan 26, 2022	Juvenile Idiopathic Arthritis
NCT03570749	Phase 2/3	Completed	Sep 24, 2018	Jan 29, 2025	Alopecia Areata
NCT03616964	Phase 3	Completed	Aug 2, 2018	Oct 20, 2021	Systemic Lupus Erythematosus
NCT03616912	Phase 3	Terminated	Aug 2, 2018	Mar 9, 2022	Systemic Lupus Erythematosus
NCT03334435	Phase 3	Completed	Mar 28, 2018	Jul 12, 2023	Atopic Dermatitis
NCT03435081	Phase 3	Completed	Feb 20, 2018	Aug 16, 2021	Atopic Dermatitis
NCT03334422	Phase 3	Completed	Nov 27, 2017	Dec 12, 2018	Atopic Dermatitis
NCT03334396	Phase 3	Completed	Nov 23, 2017	Aug 16, 2019	Atopic Dermatitis
NCT02758613	Phase 1	Completed	May 1, 2016	Jul 1, 2016	Healthy
NCT02708095	Phase 2	Completed	Mar 24, 2016	Nov 9, 2017	Systemic Lupus Erythematosus
NCT02265705	Phase 3	Completed	Oct 1, 2014	May 1, 2017	Rheumatoid Arthritis
NCT01885078	Phase 3	Completed	Jun 27, 2013	Nov 12, 2020	Rheumatoid Arthritis

Competing Products

20 competing products in Areata Alopecia

See all competitors

Product	Company	Stage	Hype Score
Baricitinib	Eli Lilly	Phase 2	52
CTP-543	Sun Pharmaceutical	Phase 2/3	65
CTP-543	Sun Pharmaceutical	Phase 3	77
Deuruxolitinib + Placebo	Sun Pharmaceutical	Phase 3	77
Baricitinib + Placebo	Eli Lilly	Phase 2/3	65
Baricitinib + Placebo	Eli Lilly	Phase 3	77
Upadacitinib + Upadacitinib Placebo	AbbVie	Phase 3	77
Upadacitinib + Placebo	AbbVie	Phase 3	77
Secukinumab + Placebo	Novartis	Phase 2	52
Daxdilimab	Amgen	Phase 2	51
Ritlecitinib	Pfizer	Pre-clinical	22
LITFULO	Pfizer	Pre-clinical	22
Ritlecitinib	Pfizer	Pre-clinical	22
Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo	Pfizer	Phase 3	76
Ritlecitinib	Pfizer	Pre-clinical	22
PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine + Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine	Pfizer	Phase 3	76
Ritlecitinib 20 mg	Pfizer	Phase 1	32
PF-06651600 + Placebo	Pfizer	Phase 2	51
Ritlecitinib higher dose + Ritlecitinib lower dose	Pfizer	Phase 3	76
Etrasimod + Etrasimod + Placebo	Pfizer	Phase 2	51

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved